English

BioStock: Cereno's CEO – "CS014 adds potential for cardiovascular disease patients"

Report this content

Cereno Scientific is a biotech company developing treatments for the number one killer in the world - cardiovascular disease. The company has been granted the approval from EMA to initiate a first-in-human phase I trial with candidate CS014 – a novel epigenetic HDAC inhibitor. Cereno’s CEO Sten R Sörensen stopped by the BioStock Studio to share more details about the news.

Read the interview at biostock.se:

Cereno's CEO: "CS014 adds potential for cardiovascular disease patients" - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Subscribe

Documents & Links

Quick facts

BioStock: Cereno's CEO – "CS014 adds potential for cardiovascular disease patients"
Tweet this